THE INFORMATION IN THE OBPHARMTM
IS INTENDED SOLELY FOR USE BY THE MEDICAL PROFESSION. IT IS NOT INTENDED FOR LAY PERSONS.
FOCUS INFORMATION TECHNOLOGY, INC. DOES NOT ASSUME ANY RESPONSIBILITY FOR ANY ASPECT OF
HEALTHCARE ADMINISTERED WITH THE AID OF THIS CONTENT. THE PRESCRIBING PHYSICIAN
MUST BE FAMILIAR WITH THE FULL PRODUCT LABELING AS PROVIDED BY THE MANUFACTURER AND RELEVANT MEDICAL LITERATURE PRIOR TO USING THE
Focus Information Technology makes no representation or warranty as to the accuracy, reliability, timeliness,
usefulness or completeness of any of the information contained in the OBPharmTM
Please review the
before using this site.
The information provided on this site is updated periodically. It is likely
that the information presented will not include all information currently
available. Keep in mind the limitations of this information.
The Food and Drug Administration (FDA) created the following rating system in 1979 to categorize the potential risk to the fetus for a given drug.
Category A: Controlled human studies have demonstrated no fetal risk
Category B: Animal studies indicate no fetal risk, but no human studies, OR adverse effects in animals , but not in well- controlled human studies
Category C: No adequate human or animal studies, OR adverse fetal effects in animal studies, but no available human data.
Category D: Evidence of fetal risk, but benefits outweigh risks.
Category X: Evidence of fetal risk. Risks outweigh any benefits.
The U.S. Food and Drug Administration (FDA) has recommended the elimination of the current pregnancy categories A, B, C, D, and X.
Instead the FDA has proposed that the pregnancy and lactation subsections of labeling should include a summary, which summarizes the risks of the medicine to the developing baby (fetus) or breast-feeding infant, and a discussion of the data supporting that summary  .
Until this labeling change becomes common
Suggestions for Prescribing Medication in Pregnant Women
Modified from: Norwitz ER,Greenberg JA.Rev Obstet Gynec ol. 2009;2(3):135-6
Use medication only if absolutely indicated.
- Avoid initiating therapy during the
- Select a medication with a proven
track record in human pregnancy.
- Use a
- Use the lowest effective dose.
- Discourage the use of over-the
counter drugs that might interact with prescription medications.
The following site contains referenced information
and useful summaries:
B C D
E F G
H I J
K L M
N O P
Q R S
T U V
W X Y
Iron sucrose (Venofer® )
Iron sucrose (Venofer® )
Insulin aspart (Novolog ®)
Insulin glargine (Lantus ®)
lispro (Humalog ®)
Insulin, NPH (Humulin® N, Novolin® N)
Regular (Humulin® R, Novolin® R)
Insulin pump, indications
Magnesium sulfate, Hypomagnesemia
Magnesium sulfate, Neuroprotection
Magnesium sulfate, Preeclampsia, Eclampsia
Magnesium sulfate, Severe asthma
Magnesium sulfate, Torsades de pointe
Methotrexate, ectopic pregnancy
Papilloma Virus (Genital Warts)
Pelvic Inflammatory Disease (PID)
Platelets, Platelets Pheresis
Postpartum Hemorrhage Algorithm
Prenatal prevention of virilization
in a female fetus with congenital adrenal hyperplasia
Ursodiol, ursodeoxycholic acid, (Actigall®)
Vaginal Yeast Infection
Pregnancy & Lactation Labeling. U.S. Department of Health & Human
Services 12/18/2009 .Accesssed 1/27/09
Norwitz ER, Greenberg JA.Antibiotics in pregnancy: are they safe? Rev Obstet
Gynecol. 2009 Summer;2(3):135-6. PMID: 19826569